The cancer-testis antigen NY-ESO-1 is a potential target antigen for immune therapy expressed in a subset of patients with multiple myeloma. We generated chimeric antigen receptors (CARs) recognizing the immunodominant NY-ESO-1 peptide 157-165 in the context of HLA-A*02:01 to re-direct autologous CD8 þ T cells towards NY-ESO-1 þ myeloma cells. These re-directed T cells specifically lysed NY-ESO-1 157-165 /HLA-A*02:01-positive cells and secreted IFNg. A total of 40% of CCR7 À re-directed T cells had an effector memory phenotype and 5% a central memory phenotype. Based on CCR7 cell sorting, effector and memory CAR-positive T cells were separated and CCR7 þ memory cells demonstrated after antigen-specific re-stimulation downregulation of CCR7 as sign of differentiation towards effector cells accompanied by an increased secretion of memory signature cytokines such as IL-2. To evaluate NY-ESO-1 as potential target antigen, we screened 78 bone marrow biopsies of multiple myeloma patients where NY-ESO-1 protein was found to be expressed by immunohistochemistry in 9.7% of samples. Adoptively transferred NY-ESO-1-specific re-directed T cells protected mice against challenge with endogenously NY-ESO-1-positive myeloma cells in a xenograft model. In conclusion, re-directed effector-and central memory T cells specifically recognized NY-ESO-1 157-165 / HLA-A*02:01-positive cells resulting in antigen-specific functionality in vitro and in vivo.
INTRODUCTION
Multiple myeloma is characterized by neoplastic transformed plasma cells in the bone marrow 1 and, in general, considered to be an incurable disease. Young patients are usually treated by the sequential application of induction, consolidation and, in some patients, maintenance therapy. Induction therapy typically consists of a combination of steroids, cytotoxic drugs, proteasome inhibitors and immunmodulatory drugs. 2 Consolidation is performed with high-dose chemotherapy followed by autologous peripheral stem cell transplantation. Using this treatment strategy, prognosis has considerably improved over the last decade and results in a 10-year survival of approximately 30%. 3 However, even this intense treatment regimen is not curative. Therefore, new additional approaches have to be developed for the eradication or control of minimal residual malignant plasma cell burden. 4 Allogeneic stem cell transfer can achieve the goal of cure in a limited number of patients depending on their current disease status, age and performance status. 5, 6 The curative effect of allogeneic stem cell transfer is, in part, an immunological effect mediated by T cells from the donor defined as graft versus myeloma effect. 7 Minor histocompatibility antigens are mainly responsible for this graft versus myeloma effect, 8 however, they are also associated with more serious complications of graftversus host disease (GvHD). Therefore, the identification of new myeloma-specific antigens, unrelated to histocompatibility antigens, is of great interest.
NY-ESO-1 is a prime target for immunotherapy, because NY-ESO-1 expression is found in a wide variety of malignant neoplasms. 9 In tumor patients, spontaneous 10 and vaccine-induced T-cell responses 11 to NY-ESO-1 can be detected. NY-ESO-1 has been shown to be expressed at the mRNA level on biopsies from multiple myeloma patients in up to 60% at relapse.
12 NY-ESO-1 is an intracellular protein whose peptides can be presented on the cell surface in the context of HLA molecules when it is ubiquitinated and degraded in the cell. 9 The 157-165 peptide is the immuno-dominant NY-ESO-1 peptide in the context of HLA-A*02:01. 13 We have developed antibodies that bind to the immunodominant peptide 157-165 of NY-ESO-1 presented in the binding groove of the HLA-A*02:01 molecule. To enhance the binding of these antibodies to the NY-ESO-1 157-165 /HLA-A*02:01 complex, we have mutated the complementarity-determining regions of the single-chain fragment to reach higher affinities, thus decreasing the threshold of antigen density required for T-cell activation. intracellular signaling domain. T cells harboring a CAR are called re-directed T cells. First-generation CARs consist of an intracellular CD3z signaling domain coupled to the singlechain antibody fragment, whereas second-generation constructs contain both a co-stimulatory domain such as CD28 and the CD3z signaling domain. 15 Recently, the use of anti-CD19 redirected T cells demonstrated significant clinical activity and induced remission in patients with advanced chronic lymphoid leukemia. 16 Here we analyzed the phenotype and functional activity of CD8 þ re-directed T cells harboring a high-affinity CAR recognizing the immuno-dominant NY-ESO-1 157-165 peptide in the context of the HLA-A*02:01 molecule. NY-ESO-1 157-165 /HLA-A*02:01 specific re-directed T cells had a predominant effector memory phenotype, lysed target cells and released antigen-specific effector cytokines. Interestingly, central memory T cells were also transduced and showed antigen-specific functionality evidenced by downregulation of CCR7 and IL-2 production in vitro. Furthermore, we tested the functional activity of the re-directed T cells in an in vivo multiple myeloma xenograft model.
RESULTS

Generation of re-directed CD8
þ effector T cells expressing CARs, which recognized the HLA-A*02:01-NY-ESO-1 157-165 peptide complex We generated re-directed T cells expressing a CAR consisting of a single-chain Fv molecule recognizing the HLA-A*02:01/NY-ESO-1 157-165 peptide complex linked to a human CH2/3 immunoglobulin domain and a CD3z signaling domain (anti-NY-ESO-1-T1-CD3z), or a CD3z signaling domain and a CD28 co-stimulatory domain (anti-NY-ESO-1-T1-CD28/CD3z).
14 As a control, re-directed T cells expressing a CAR-recognizing carcinoembryonic antigen (CEA) with a CD28 co-stimulatory domain and a CD3z signaling domain (anti-CEA-BW-CD28/CD3z) were also used. 17 The schematic representation of the re-directed T cells is shown in Supplementary Figure S1 . CD8 þ T cells isolated from human peripheral blood were retrovirally transduced to achieve cell surface expression of CARs as assessed by detecting the human CH2/3 immunoglobulin domain (hIgG) using flow cytometry (Figures 1a-d) . After transduction, approximately 45% (median 44.42% for all constructs, range: 11.06-79.05%) of CD8 þ T cells expressed the respective receptor. Antigen recognition of the immuno-receptor on the cell surface was measured by HLA-A*02:01/NY-ESO-1 157-165 peptide tetramer binding (Figures 1e-h ). The percentage of T cells expressing the anti-NY-ESO-1-CAR mirrored tetramer staining with no significant difference between anti-NY-ESO-1-T1-CD28/CD3z and anti-NY-ESO-1-T1-CD3z constructs. As expected, the tetramer did not bind to the control anti-CEA-BW-CD28/CD3z CAR that recognizes CEA.
Anti-NY-ESO-1-transduced T cells included subpopulations of effector and memory phenotype We hypothesized that these CAR transduced T cells included a population of effector (T EFF ) and memory T cells (T M ). Therefore, we utilized six-color flow cytometry analysis (anti-hIgG, anti-CCR7, anti-CD57, anti-CD45RA, anti-CD28, anti-CD27) to delineate subpopulations of re-directed T cells (hIgG-positive cells) as depicted in Supplementary Figure S2 . T cells were analyzed from 11 consecutive donors 3 days after transduction. Re-directed T cells included a CCR7
À population, which could be separated into subpopulations with T EFF phenotype (CCR7
. 18 Interestingly, the CCR7 þ population included cells with a central memory ( (Figure 2 ). Comparison of 11 different donors showed no significant overall differences between T cells transduced with anti-NY-ESO-1-T1-CD28/CD3z or anti-NY-ESO-1-T1-CD3z (Supplementary Figure S3) . However, transduction of the anti-NY-ESO-1-T1-CD28/CD3z and anti-NY-ESO-1-T1-CD3z resulted in a statistically significant different composition of single subphenotypes that included T EMRA (effector memory re-expressing CD45RA), late and early T EM , and T EFF . There was no statistical difference in the composition of subphenotypes between transduced and non-transduced cells (Supplementary Figure S3) . on the cell surface as calculated by Mann-Whitney U-test (Supplementary Figure S4) .
Anti-NY-ESO-1 re-directed T cells lysed target cells and secreted antigen-specific IFNg As the majority of the transduced T cells displayed an effector or an effector memory phenotype, we were interested in determining their antigen-specific functionality in vitro.
Stable-transfected HLA-A*02:01-positive T2 cells expressing HLA-A*02:01-restricted NY-ESO-1 peptides were used as target cells.
Peptides with different length were used to test for antigen specificity (NY-ESO-1 157-165 (T2-1B, Figure 3a) , NY-ESO-1 157-167 (T2-1A, Figure 3b ) and NY-ESO-1 155-163 (T2-1C, Figures 3e and f) ). Only T2-1B cells were engineered to express the NY-ESO-1 peptide 157-165 in the HLA-A*02:01 groove, which is recognized by the anti-NY-ESO-1-CAR constructs. T cells transduced with anti-NY-ESO-1-T1-CD28/CD3z mediated significantly higher specific lysis compared with re-directed T cells expressing anti-NY-ESO-1-T1-CD3z as calculated over ten pooled experiments (Figure 3c ).
Similar to the observation of the specific lysis, re-directed T cells expressing anti-NY-ESO-1-T1-CD28/CD3z secreted significantly 
CCR7
þ /anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells downregulated CCR7 and expressed IL-2 after re-stimulation Anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells included a population with a central memory T-cell phenotype. Upon activation, central memory T cells differentiate into effector cells and downregulate CCR7 expression. We speculated that activation of CCR7 þ /anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells resulted in differentiation towards CCR7 À T EFF and T EM cells. Therefore, we sorted CCR7 þ /anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells and re-stimulated them with anti-idiotypic Fab AI or control Fab, respectively. Activation of the CCR7 þ /anti-NY-ESO-1-T1-CD28/CD3z re-directed T-cell population resulted in a significant, antigen-specific reduction of CCR7 þ /anti-NY-ESO-1-T1-CD28/ CD3z re-directed T cells and a significant increase of CCR7 À / anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells (Figure 4a ). In contrast, sorted re-directed CCR7
À /anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells showed no significant change of CCR7 expression suggesting no phenotypical change after activation. Furthermore, re-stimulation with anti-idiotypic Fab AI of sorted, CCR7
þ /anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells demonstrated antigen-specific release of IL-2 and only low levels of IFNg (Figures 4b, c) . In contrast, sorted CCR7
À /anti-NY-ESO-1-T1-CD28/ CD3z re-directed T cells produced primarily IFNg and additionally IL-2. However, IL-2 secretion was significantly lower compared with sorted CCR7 þ /anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells. NY-ESO-1 protein expression in bone marrow biopsies of multiple myeloma patients We generated a tissue microarray with bone marrow biopsies from 78 multiple myeloma patients to investigate the NY-ESO-1 expression levels. If tumor cells represented less than 30% of the cellularity, the cores were excluded from analyses. Tumor cells were identified by morphology and CD138 staining. Staining for NY-ESO-1 was scored in a three-tiered system ( þ : faint, þ þ : moderate and þ þ þ : strong) and regarded as positive, if at least 10% of tumor cells showed either a cytoplasmic and/or a nuclear staining. In all, 65 of 72 (90.3%) evaluable myelomas did not stain for NY-ESO-1, whereas 7 of 72 (9.7%) evaluable myelomas expressed NY-ESO-1. Interestingly, 5 of the 7 (71%) myelomas showed a moderate to strong expression (Figures 5e and f) , whereas in one poorly differentiated myeloma, a faint but distinct cytoplasmic expression was observed (Figure 5d) . A homogeneous expression pattern in tumor cells was observed in all cases except for one where a strong staining was present in only 20% of tumor cells (data not shown).
Anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells were protective in a xenograft model with HLA-A*02:01 þ /NY-ESO-1 myeloma cells
The above findings indicated antigen-specific functionality of anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells in vitro and NY-ESO-1 expression in primary patient material. Therefore, we established a xenograft model in NOD/SCID/g c null (NSG) mice to test whether these re-directed T cells could mediate a protective effect against the HLA-A*02:01/ NY-ESO-1-positive myeloma cell line U266. Mice were sub-lethally irradiated and subsequently intravenously injected with U266 cells to establish growth of the myeloma cells in the bone marrow. U266 cells secrete a human IgE paraprotein that was measured in serum samples of the animals as a surrogate marker for tumor burden (Supplementary Figure S6A) . Histopathological analysis revealed tumor growth in the bone marrow (Supplementary Figure S6B) , which was confirmed by flow cytometry analysis of the bone marrow of the spine as well as the femur and tibia (Supplementary Figure S6C) . Intravenous injection of 10 6 anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells or 10 6 anti-CEA-BW-CD28/CD3z re-directed T cells did not significantly impact on tumor growth as determined by human IgE levels ( Figure 6a ). Therefore, we increased the dose of re-directed T cells to 10 7 cells for anti-NY-ESO-1-T1-CD28/CD3z and anti-CEA-BW-CD28/CD3z re-directed T cells. Intravenous injection of 10 7 anti-NY-ESO-1-T1-CD28/CD3z re-directed CD8 þ T cells protected mice as measured by human IgE (Figure 6b ). Human IgE levels were significantly different at various time points between the treated and untreated group for up to day 50 after injection of anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells as calculated by Mann-Whitney U-test. In contrast to the treatment with 10 6 anti-CEA-BW-CD28/CD3z re-directed T cells, mice treated with 10 7 anti-CEA-BW-CD28/CD3z re-directed T cells succumbed of massive gastrointestinal toxicity. However, mice in which human IgE analysis could be performed exhibited an increased concentration of human IgE. To evaluate persistency of adoptively transferred anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells, mice were analyzed for anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells at various time points after transfer. Analysis of peripheral blood mononuclear cells revealed persistency of CCR7 À /anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells in 4 out of 10 mice until day 30 after adoptive transfer (Supplementary Figure S6D) . 16 Our data demonstrated the functional activity of anti-NY-ESO-1 re-directed T cells. Interestingly, the majority of anti-NY-ESO-1 CD8 þ re-directed T cells consisted of cells with an effector memory phenotype that secreted IFNg when stimulated with NY-ESO-1 157-165 .
We retrovirally transduced CD8 þ T cells with CARs recognizing the HLA-A*02:01/ NY-ESO-1 157-165 complex. The intracellular moiety consisted either of a CD3z signaling domain (anti-NY-ESO-1-T1-CD3z) or a combined CD28/CD3z signaling domain (anti-NY-ESO-1-T1-CD28/CD3z). Both constructs achieved similar transduction efficiencies and were able to recognize the target antigen in a specific manner (Figures 1 and 3) . However, the additional CD28 signaling resulted in significantly increased target cell lysis and IFNg release. Our data are in line with data from Willemsen et al., 21 who previously reported that activation of a HLA class I restricted CAR harboring a CD28 co-stimulatory and intracellular FceRIg domain resulted in increased lytic capability and cytokine secretion in comparison to CAR-positive cells expressing the FceRIg domain. In contrast, classical CARs that bind to cell surface molecules do not mediate elevated cytolysis but do show increased IFNg release. 
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construct resulted in unspecific cytolysis and IFNg release of HLA class I target cells, which did not express the MAGE-A1 peptide. 21 We employed flow cytometry to delineate subpopulations of anti-NY-ESO-1-CAR-transduced T cells ( Figure 2) . As an effective immune response is comprised of multiple subsets of T cells including memory and effector cells, 24 it is important to elicit a similar composition of re-directed T-cell subsets. Such multifunctionality is of special interest when immune therapy is intended to control minimal tumor burden over time as is the case in multiple myeloma patients after high-dose chemotherapy and autologous stem cell transplantation. CD8 þ T cells can be classified in naïve, T EFF and T M cells, depending on their antigen experience, activation state, longevity and proliferation capacity. 24 Even if the lineage development of CD8 þ T M cells is not finally understood, different subpopulations of CD8 þ T M cells are phenotypically and functionally characterized. T CM are phenotypically described as CCR7
Circulating or tissue-resident CD8 þ T EM display immediate effector function upon antigen recognition. T CM reside in the T-cell areas of lymphoid tissues where they can mount a rapid recall response after recognition of their cognate antigen presented by dendritic cells. 26 We phenotypically identified multiple effector and memory subpopulations within the anti-NY-ESO-1-CARs re-directed T cells based on consensus models of 3 to 7 marker analysis.
27-31 Interestingly, we found primarily early and late effector memory phenotypes in the anti-NY-ESO-1 re-directed T cells (CCR7
and small populations of fully differentiated effector T cells (CCR7
As the majority of anti-NY-ESO-1 re-directed T cells had an early and late T EM phenotype, the immediate antigen-specific response in vitro and the protective effect in vivo are presumably mediated by T EM cells. Furthermore, a minor population of central
Barber et al. 32 showed an early effector phenotype of chimeric NKG2D expressing CD8 þ T cells after 10 days of culture. Neeson et al. 33 reported that LeY re-directed T cells mainly displayed effector and central memory phenotypes by the end of the transduction. These differences may result from the different T-cell activation and retroviral transduction protocols. In both publications, T cells were stimulated by anti-CD3 (OKT3) and IL-2 for 3 days and subsequently retrovirally transduced for 5 or 7 days, respectively. In contrast, we activated T cells with anti-CD3 and anti-CD28 monoclonal antibodies for 2 days followed by the transduction which lasted for 4 days via 293T co-culture. Neeson et al. 33 analyzed a second-generation CAR construct harboring a CD28/CD3z domain and Barber et al. 32 a primary construct expressing the CD3z chain only. In our data, analysis of 11 different donors revealed only slight differences in the phenotypical composition of anti-NY-ESO-1 re-directed T cells. Notably, anti-NY-ESO-1-T1-CD3z re-directed T cells displayed higher amounts of early T EM , less late T EM cells and more T EMRA cells compared with anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells. Interestingly, the non-transduced population of CD8 þ T cells displayed the same distribution of subpopulations indicating that there was not a preferential transduction of a certain subphenotype. Furthermore, the expression level of anti-NY-ESO-1-T1-CD28/CD3z did not vary between T CM and T EM . Under the assumption of equal capacity to produce the anti-NY-ESO-1-T1-CD28/CD3z, this observation is suggesting that both subpopulations were transduced with the same efficiency.
We studied the cytokine profile of anti-NY-ESO-1-T1-CD28/CD3z re-directed subpopulations after cell sorting for CCR7 þ and CCR7 À expression (Figures 4b and c) . Restimulation of CCR7 À /anti-NY-ESO-1-T1-CD28/CD3z T cells resulted in the simultaneous release of IFNg and IL-2, supporting the classification of these re-directed T cells as early effector memory T cells. 34 Furthermore, CCR7 þ / anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells released significantly more IL-2 than CCR7
À / anti-NY-ESO-1-T1-CD28/CD3z redirected T cells and CCR7
À / anti-NY-ESO-1-T1-CD28/CD3z T cells secreted more IFNg than CCR7 þ / anti-NY-ESO-1-T1-CD28/CD3z T cells. This is in accordance with previously reported data, which human IgE (ng/ml) days after intravenious injection of U266 
CCR7
þ T cells release mainly IL-2, the signature cytokine of central memory cells. 35 The generation of re-directed central memory cells is of special interest as they might be able to generate functional effector T cells after antigen re-encounter and, thus, be able to control residual dormant tumor cells. Terakura et al. 36 reported a method to generate second-generation CAR-specific CD8 þ T cells derived from virus-specific central memory cells. An elaborate method was employed to obtain virus-specific T cells from CD45RA À
CD62L
þ CD8 þ central memory T cells from donor blood. These cells were able to expand in vitro and form a large pool of CARpositive effector T cells exhibiting target-antigen-specific effector functions in vitro. Although memory lineage development is still controversial, 27 data suggest that secondary activation of T CM results in strong proliferation and differentiation into T EFF . 35 In our model re-stimulation of CCR7 þ / anti-NY-ESO-1-T1-CD28/CD3z T cells led to downregulation of CCR7 supporting the hypothesis of differentiation of central memory into effector T cells. The loss of CCR7 allows T cells to migrate out of the lymphatic system. These cells patrol non-lymphoid tissues and are potentially capable to invade neoplastic tissues.
We investigated the ability of anti-NY-ESO-1-T1-CD28/CD3z redirected T cells to recognize endogenously NY-ESO-1-expressing cells and evaluated their potential for immunotherapy of multiple myeloma. HLA-A*02:01-positive multiple myeloma cells with endogenous NY-ESO-1 expression were lysed at a target:effector ratio of 4:1 by anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells. Cell lines stably transfected with the NY-ESO-1 157-165 peptide already showed antigen-specific lysis at a target:effector ratio of 1:1. We attribute this observation to the lower expression of antigen in endogenously NY-ESO-1-expressing cells. We screened a large cohort of 78 bone marrow samples from multiple myeloma patients and showed that 9.7% expressed the NY-ESO-1 protein.
Atanackovic et al. 37 reported a mRNA expression of 7% for NY-ESO-1 in 55 screened bone marrow biopsies from multiple myeloma patients employing reverse transcriptase-polymerase chain reaction. Furthermore, de Carvalho et al.
38 measured NY-ESO-1 expression in 55 cases of multiple myeloma and received a positive mRNA signal in 26% of the cases and immunohistochemistry of 27 samples revealed NY-ESO-1 protein expression in 7.4% of cases.
We established a xenograft multiple myeloma model to evaluate the functional activity of anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells in vivo. 39 Human IgE secreted by U266 was measured as a surrogate to quantify systemic tumor burden. U266 cells grew in the bone marrow niche, which finally led to lytic bone lesions and severe hind leg paralysis of mice (data not shown). Mice treated with anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells 5 days after U266 injection were protected against tumor growth. At 30 days after adoptive transfer of anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells, 90% of the mice started to develop GvHD. We speculate that irradiation of NOD/ SCID/g c null mice carrying a Prkdc mutation led to irreparable tissue damage. 40 This damaged and presumably inflamed tissue might have induced human T cells to cause xeno-GvHD disease. Control mice treated with high doses of anti-CEA-BW-CD28/CD3z re-directed T cells (10 7 ) developed acute gastro-intestinal toxicity most likely due to the recognition of murine CEA. However, some of these mice developed measurable hIgE levels at early time points indicating in vivo specificity of the anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells (Figure 6b) . Furthermore, anti-NY-ESO-1-T1-CD28/CD3z transduced T cells were present in 40% of peripheral blood samples of treated animals 30 days after adoptive transfer. Interestingly, anti-NY-ESO-1-T1-CD28/CD3z redirected T cells found in the blood did not express CCR7, indicating an effector phenotype of re-directed T cells (Supplementary Figure S6D) . This finding is consistent with the flow cytometry data showing mainly a CCR7
À phenotype of anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells after transduction (Figure 2) . Zhao et al. 41 also reported on a gradual loss of CAR expression but was able to prolong T-cell persistence in vivo by adding a 4-1BB cytoplasmic domain to the CD28/CD3z moiety. Most recently, the formation of central memory was detected in re-directed T cells with CARs consisting of a 4-1BB cytoplasmic domain and a CD3z signaling domain after the transfer into patients with chronic lymphocytic leukemia. 42 In summary, we demonstrated that NY-ESO-1 re-directed T cells with a high-affinity CAR exhibit strong effector functions without loss of specificity when CD28 signaling is provided through the CAR. We phenotypically identified re-directed effector-and central-memory T cells, which displayed antigen-specific signature cytokine release in vitro. In vivo, anti-NY-ESO-1-T1-CD28/CD3z re-directed T cells protected mice against NY-ESO-1 þ myeloma cells. As we also found expression of NY-ESO-1 in a subset of patients, the results are a strong rational for the further testing of NY-ESO-1 specific second-generation CARs in pre-clinical and later in clinical trials for myeloma patients. Future studies need to examine the potentially long-lasting CCR7
þ re-directed memory T cells as a strategy to not only resolve existing primary tumors but also to keep residual or dormant tumor cells under control for long time. Approaches have to be developed to exploit the full therapeutic and protective potential of these already existing memory T cells.
MATERIALS AND METHODS
Cell lines
Stable-transfected HLA-A*02:01-positive T2 cell lines T2-1A, T2-1B and T2-1C expressing HLA-A*02:01-restricted NY-ESO-1 peptides 157-167 (T2-1A), 157-165 (T2-1B) and 155-163 (T2-1C) were generated as previously described. 13 293T, U266 and LS-174T cells were purchased from ATCC (Manassas, VA, USA), Z-T-273 was generated in our lab. All tumor cell lines were cultivated in standard R10 media (RPMI1640 GlutaMax supplemented with 10% fetal bovine serum (v/v), 50 U ml 
Generation of CAR
The Fab antibody-fragment T1 binding to HLA-A*02:01/NY-ESO-1 157-165 complexes was selected and cloned as previously described.
14 After conversion into a single-chain fragment and flanking with NcoI and BamHI restriction sites, the construct was cloned into the pBullet vector, 43 containing either a human CD3z and CD28 signaling domain 14, 44 or a human CD3z domain alone, 22 which in the following are termed either anti-NY-ESO-1-T1-CD28/CD3z or anti-NY-ESO-1-T1-CD3z, respectively.
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The BW431/26-CD28/CD3z CAR construct, which directly recognizes an epitope of the human CEA served as control 45 and is called anti-CEA-BW-CD28/CD3z in this study.
Retroviral transduction of peripheral blood CD8
þ T cells
Peripheral blood mononuclear cells were obtained from healthy donors by Ficoll Paque Plus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density gradient centrifugation. CD8 þ T-cell subsets were isolated using MACS microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's protocol. Positive selection with anti-human CD8 microbeads typically resulted in a X95% pure CD8 þ population. Purified CD8 þ T cells were cultivated for 48 h in R10 media in the presence of 400 IU ml À 1 human recombinant IL-2 (ImmunoTools, Friesoythe, Germany) and anti-human OKT3 mAb and anti-human CD28 mAb (each at 100 ng ml À 1 ). For production of infectious gibbon-ape leukemia virus pseudotyped retroviruses, 293T cells were seeded at 2.5 Â 10 5 cells per well (six-well plate) and co-transfected with the retroviral helper plasmids pHIT and pCOLT (each 0.75 mg DNA) together with the retroviral expression vector DNA (1.5 mg DNA) using 12 ml Fugene transfection reagent per well (Roche Diagnostics GmbH, Mannheim, Germany, according to the manufacturer's protocol).
Activated CD8 þ T cells were infected for 96 h in the presence of 100 U ml À 1 IL-2 by co-cultivation with 293T cells, which are transiently producing high titers of infectious retrovirus. CD8 þ T cells were harvested and monitored for CAR expression using flow cytometry.
To expand CAR-transduced T cells, they were plated at a density of 1 Â 10 6 per ml and expanded by co-cultivation with T2-1B cells at an effector:target ratio of 4:1 in 100 IU ml À 1 IL-2. Media was changed weekly and re-directed T cells were stimulated with freshly added T2-1B cells.
Immunofluorescence staining and analysis Cells were washed in FACS buffer (PBS, 2% heat-inactivated FCS, 5 mM EDTA, 0.01% sodium azide) and surface stained with directly labeled or biotinylated antibodies (20 min at 4 1C), or with peptide-MHC class I tetramer complexes (30 min at room temperature (RT)). Thereafter, cells were fixed using 500 ml of FACSLyse buffer (BD Biosciences) (10 min at RT). Cells were then washed, resuspended in FACS buffer and stained with tandem conjugates (20 min at RT). After washing, cells were resuspended in FACS buffer and analyzed by flow cytometry. Flow cytometry analysis was performed using a LSR II, FACSCanto II, FACSCalibur or FACScan (BD Biosciences). All data were analyzed using FlowJo software (Tree Star, Asland, OR, USA). At least 150 000 cells were collected for six-and fourcolor flow cytometry analysis.
Immunoflourescence microscopy Z-T-273 and 734B cell lines were plated over night at a density of 5 Â 10 4 cells per well. U266 cells were stained first, and then spun down. Cells were stained with 10 mg ml À 1 T1 or control mAb AffiniPure Goat anti-mouse IgG, Fc specific for 1 h at 4 1C. After washing, the secondary staining was performed with 2 mg ml À 1 AffiniPure F(ab') 2 Frag Goat Anti-Human IgG-PE for 30 min at RT. Following another washing step, cells were analyzed using a Zeiss 200 M microscope (Carl Zeiss AG, Munich, Germany) and a Â 100 objective.
Patients and biopsy specimen selection 
Tissue microarrays and immunohistochemistry
The presence of NY-ESO-1 in actual multiple myeloma tumor tissue was analyzed by immunohistochemistry. Therefore, tissue microarrays from paraffin embedded, EDTA-decalcified bone marrow biopsies from multiple myeloma patients were generated as published, using two tissue cores as small as 0.6 mm. 46 Immunohistochemistry using the NY-ESO-1 clone E978 (Zymed Laboratories Inc., South San Francisco, CA, USA) was carried out on a BenchmarkXT platform (Ventana Medical Systems, Tucson, AZ, USA). Antigen retrieval was performed using the conditioning buffer CC1 (Ventana Medical Systems). The reaction was completed with the horse radish peroxidase detection kit Uview mono HRP (Ventana Medical Systems) according to the manufacturer's protocol.
Europium release assay
Specific cytotoxicity of CAR-grafted T cells was analyzed by an europium release assay according to the manufacturer's protocol (Perkin Elmer, Waltham, MA, USA) with minor modifications. Briefly, target cells (T2-1A, T2-1B, T2-1C and U266) were labeled with 2,2 0 :6 0 ,2 00 -terpyridine-6, 6 00 -dicarboxylic acid acetoxymethylester (BATDA) (2 h at 37 1C). After five washing steps, target cells were seeded at a density of 10 4 cells per 96-well and co-cultured with effector cells at different effector:target ratios (2 h at 37 1C). Supernatant was harvested and incubated with DELFIA Europium solution (15 min at RT) under constant vibration. The ligand released from dead cells forms together with the europium a highly stable fluorescent chelat (EuTDA), which was measured in a time-resolved Victor 2 fluorometer (Perkin Elmer). Maximal EuTDA formation was determined as the mean of three wells of target cells lysed with TritonX buffer (150 mM NaCl, 50 mM Tris-HCL, 10 mM MgCl 2 , 1% Triton X (w/v)). Background and spontaneous release were determined from triplicate wells containing R10 media only or target cells alone, respectively.
The specific cytolysis of target cells (%) was calculated by the equation: 100 Â (experimental release (counts) À spontaneous release (counts))/ (maximum release (counts) À spontaneous release (counts)).
Cell sort
To isolate CCR7 þ and CCR7 À CAR-grafted T-cell subsets, CD8 þ T cells were stained with hIgG and CCR7 antibody and sorted to 490% purity using FACSAriaII (BD Biosciences). Cells were either used for in vivo experiments or plated in a pre-coated 96-well flat bottom plate (2 mg ml Xenograft model NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice, commonly known as NOD scid gamma, were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and maintained under specific pathogen-free conditions on Institutional Animal Care and Use Committees protocols. Mice were irradiated with a single fraction of 240 Rad followed by intravenous (i.v.) injection of 10 7 U266 cells. 39 A total of 10 6 U266 cells secreted about 300 ng ml À 1 per 24 h of human IgE in vitro. To monitor growth of malignant plasma cells in vivo, blood samples were taken after inoculation. Sera were collected and hIgE production analyzed by ELISA. To confirm U266 growth in the bone marrow of mice, tibias were resected and subsequently decalcified and H&E stained (Pathology Department, Providence Portland Medical Center, Portland, OR, USA). At 5 days after tumor cell injection, 10 6 -10 7 re-directed CD8 þ T cells were administered i.v. followed by six bi-daily injections of 90 000 IU IL-2.
Statistical analysis
Data were analyzed with Graph Pad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA). Student's unpaired or paired t-tests and Mann-Whitney U-test were performed between two groups of interest.
